Our office is now accepting clients for representation who have suffered vision damage from a condition called pigmentary maculopathy due to the use of the drug Elmiron, a medication used to treat interstitial cystitis.
Interstitial cystitis is a bladder condition which is associated with associated with a number of symptoms such as pelvic pain, pressure or discomfort in the bladder or pelvic region, and urinary frequency or urgency. Most — but not all — sufferers of interstitial cystitis are women. This is a medication which is usually prescribed by a urologist or a gynecologist.
Elmiron is a drug which is used to treat this condition. Most people who take Elmiron take it on a long-term basis, and recent studies and medical reports are showing that usage of this drug causes a condition called pigmentary macuolpathy.
Symptoms of pigmentary macuolpathy include:
- blurred vision
- difficulty reading
- poor transitions from light to dark
- dark spots in your vision
- straight lines appearing curved
- muted, less vivid color perception
- changes in eye color
Review of the early data when this medication was being approved is that a number of the test subjects were experiencing visual symptoms and there were a number of adverse event reports shortly after its release.
In the United States, there are no required warnings on the label and the label also contains no contraindications or precautions on its label. However, Canadian authorities did require label changes to warn of visual problems associated with long term use of Elmiron. This shows that the manufacturer was well aware of the problems associated with this medication, yet continued to withhold this information from prescribing doctors and the patients who were using this medication.
Our office stands ready to assist users of Elmiron recover the compensation they deserve. Contact us for a free, no-obligation consultation if you have any concerns about whether the use of Elmiron has caused injury or damage to your eyes or vision.
